Every 8-K that Merit Medical Systems Inc (MMSI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MMSI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MMSI filings page.
Merit Medical Systems, Inc. (MMSI) reported a leadership transition in its global operations organization and related executive employment terms. On August 14, 2026, Merit eliminated the Chief Operating Officer role, changing Neil W. Peterson’s title to Senior Advisor; he has given notice to resign as an employee effective March 5, 2027.
Effective August 31, 2026, Merit appointed Sheri Lewis as Executive Vice President of Global Operations. Her employment agreement provides a $600,000 annual base salary, a $400,000 signing bonus, and eligibility for an annual bonus starting in fiscal 2026 with a 60% of base salary target (pro-rated for 2026) and a 200% of base salary maximum, plus participation in the 2026 Equity Incentive Plan.
If Lewis is terminated without cause or resigns for good reason (outside a change of control), she is entitled to Accrued Obligations and a lump sum equal to the greater of one year of base salary or a formula based on her three-week salary rate multiplied by completed years of service (capped at 26 years), along with pro-rated performance stock units. If such a termination occurs in connection with a change of control, she instead receives Accrued Obligations and a lump sum equal to 2x the sum of her then-current base salary and the average of her bonuses for the prior three full fiscal years, plus vesting of target performance stock units.
Merit Medical Systems, Inc. reported strong second-quarter 2026 results, with net sales of $418.843 million, up 10% year-over-year and 9% on a constant currency basis. Management highlighted 9% organic, constant currency revenue growth excluding a strategic divestiture and 10% growth in U.S. sales. GAAP gross margin improved to 51.4% and non-GAAP gross margin to 55.8%. GAAP net income was $38.8 million ($0.65 per diluted share), while non-GAAP net income was $71.3 million ($1.19 per share), an 18% year-over-year increase.
GAAP operating margin rose to 14.4% and non-GAAP operating margin to 22.6%. For the first six months, free cash flow was $76.6 million. As of June 30, 2026, the company held $448.7 million in cash and cash equivalents, total debt obligations of $747.5 million, and approximately $697 million of available borrowing capacity.
Merit raised its full-year 2026 outlook, now guiding total revenue to $1.631–$1.643 billion (7.6–8.4% growth) and non-GAAP earnings per share to $4.25–$4.35, implying 11–14% growth, compared with prior EPS guidance of $4.01–$4.15. Management continues to target its three-year Continued Growth Initiative financial objectives through 2026.
Merit Medical Systems, Inc. reported results from its 2026 annual meeting and related governance actions. Shareholders approved the 2026 Equity Incentive Plan, which authorizes awards such as stock options, restricted stock, and restricted stock units, and the 2026 Employee Stock Purchase Plan, allowing eligible employees to buy common stock through payroll deductions at a discount.
Shareholders elected Martha G. Aronson, Lonny J. Carpenter and Scott R. Ward to three-year board terms and Lynne N. Ward to a one-year term, and gave majority support to the advisory say-on-pay vote. They also ratified Deloitte & Touche LLP as independent registered public accounting firm for the year ending December 31, 2026. Following plan approval, the board adopted a base form restricted stock unit award agreement for directors and approved Fifth Amended and Restated Bylaws, which fully replace the prior bylaws.
Merit Medical Systems, Inc. reported solid first quarter 2026 results, with net sales of $381.9 million, up 7.5% from $355.4 million a year earlier. GAAP diluted earnings per share were $0.68 versus $0.49, and non-GAAP EPS rose 9% to $0.94.
GAAP gross margin held at 48.4%, while non-GAAP operating margin improved to 19.7% from 19.3%. Free cash flow increased 26% to $24.7 million. Revenue by product category grew 6% in Foundational and 10% in Therapeutic on a reported basis.
For full-year 2026, Merit guides total revenue to $1.612–$1.634 billion, implying 6.3–7.8% GAAP growth, and maintains non-GAAP EPS guidance of $4.01–$4.15, or 5–8% growth. Updated guidance incorporates the April 1 acquisition of View Point Medical’s OneMark System, expected to add $2–$4 million of 2026 revenue and dilute prior non-GAAP EPS guidance by about $0.05.
Merit Medical Systems, Inc. furnished updated historical revenue breakdowns to align with its new foundational and therapeutic product categories. The data covers the years ended December 31, 2025, 2024, 2023 and 2022, and quarterly results for each three‑month period from March 31, 2024 through December 31, 2025.
For 2025, revenue was $1,515,906 thousand, including $1,028,540 thousand from foundational products and $487,366 thousand from therapeutic products. The company also provided 2025 and 2024 quarterly revenues by category and detailed platform-level revenues within each category, such as Access, OEM, Cardiac Therapies and Oncology.
The company states this information is supplemental, does not revise or restate previously reported consolidated financial statements, and is furnished under Regulation FD rather than filed for liability purposes or automatic incorporation into other Securities Act or Exchange Act filings.
Merit Medical Systems has acquired View Point Medical in a merger, making View Point a wholly owned subsidiary and adding its OneMark Detection Imaging System and OneMark Tissue Markers to Merit’s therapeutic oncology portfolio. Total consideration, including assumed liabilities, is about $140 million, with $90 million paid in cash at closing and two deferred payments of $25 million each due by the first and second anniversaries of closing.
From April 1 through year-end 2026, the deal is projected to add $2–$4 million of revenue and dilute previously forecast non-GAAP earnings per share by about $0.05, including roughly $2.0 million of lower interest income on cash used. For 2027, revenue contribution is projected at $14–$16 million, with at least 20% annual sales growth, about 70% non-GAAP gross margins and accretion to non-GAAP operating margins, while remaining dilutive to GAAP earnings in 2026–2027 and accretive thereafter.
Merit Medical Systems reported strong fourth quarter and full year 2025 results and issued higher 2026 guidance. Full year 2025 net sales were $1,515.9 million, up 12% from 2024, with GAAP diluted EPS of $2.13 and non-GAAP EPS of $3.83, both increasing year over year.
Profitability improved as GAAP gross margin rose to 48.7% and non-GAAP gross margin to 53.7%, while GAAP operating margin reached 12.2% and non-GAAP operating margin 20.3%. Free cash flow was $215.7 million, up 16%, supported by $297.4 million in operating cash flow and $81.7 million of capital expenditures.
For 2026, Merit guides revenue to $1.610–$1.630 billion, implying 6%–8% growth, and non-GAAP EPS to $4.01–$4.15, 5%–8% above 2025. Management highlights stable constant-currency growth, improving margins, strong cash generation and continued execution of its multi-year growth initiatives program.
Merit Medical Systems, Inc. reported that it has issued a press release with preliminary unaudited revenue for the quarter ended December 31, 2025 and outlined plans to report full fourth-quarter and full-year 2025 results along with fiscal 2026 guidance.
The company also disclosed significant board changes. Longtime leader Fred P. Lampropoulos resigned as a director and Chair of the Board effective January 4, 2026, after previously concluding his service as Executive Chair, President and Chief Executive Officer, citing personal reasons and with no disagreement related to management, the board, or financial reporting and controls. Merit entered into a three-month consulting agreement with him at $250,000 per month. Effective January 5, 2026, the board appointed former Lead Independent Director F. Ann Millner, Ed.D. as Chair and reduced the board size from eleven to ten members.
Merit Medical Systems furnished a Form 8-K to share a press release with updates on U.S. reimbursement and commercial strategies for its WRAPSODY® Cell-Impermeable Endoprosthesis. The press release is attached as Exhibit 99.1 and provides product-related commercial and reimbursement developments. The disclosure under Item 7.01 is furnished pursuant to General Instruction B.2 and is not deemed “filed” under the Exchange Act, nor incorporated by reference into other filings.
Merit Medical Systems (MMSI) closed the C2 CryoBalloon acquisition. The company reported that on November 3, 2025, it completed the purchase of the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The deal follows a definitive asset purchase agreement previously announced.
The disclosure is furnished under Item 7.01 (Regulation FD) and, along with Exhibit 99.1, is not deemed “filed” under the Exchange Act. The company also included a comprehensive safe harbor statement regarding forward-looking statements tied to integration, development, commercialization, and performance outcomes related to the C2 CryoBalloon assets.
Merit Medical Systems, Inc. filed a Form 8-K after issuing a press release with its operating and financial results for the quarter ended September 30, 2025. The company also held a conference call with a live webcast and slide presentation to discuss these third-quarter results and its outlook.
The press release, titled “Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance,” and the conference call slides are provided as Exhibits 99.1 and 99.2. Merit highlights both GAAP and non-GAAP financial measures and states that detailed reconciliations to comparable GAAP figures are included in these materials. The company explains that it does not provide full GAAP guidance for certain metrics because it cannot reasonably predict the impact of acquisition-related items, non-cash amortization, severance, litigation, and regulatory changes on future results.
Merit Medical Systems (MMSI) announced a definitive asset purchase agreement to acquire the C2 CryoBalloon device and related technology from Pentax of America, Inc., a subsidiary of PENTAX Medical. The total purchase consideration is $22 million, including $19 million cash at closing and up to $3 million in contingent payments tied to milestones.
The closing is expected in Q4 2025, subject to satisfaction or waiver of customary closing conditions. Merit referenced non-GAAP measures in its press release and stated that a quantitative reconciliation to GAAP is not available without unreasonable effort.
Merit Medical Systems has completed a planned leadership transition, appointing Martha G. Aronson as President and Chief Executive Officer effective October 3, 2025. The Board also expanded from ten to eleven members and named her to the Board, while longtime leader Fred P. Lampropoulos moves from President and CEO to Executive Chairman through January 3, 2026 and will remain Board Chair thereafter.
Aronson’s employment terms include a $1,000,000 annual base salary, a $250,000 signing bonus, eligibility for an annual bonus targeting 100% of salary (up to 200%), and participation in the long-term equity plan with an expected initial equity award valued at $5,500,000 plus an additional $4,125,000 in performance and restricted stock units. She will also receive a $12,000 monthly transition allowance through September 30, 2026 and relocation and legal fee reimbursements. Lampropoulos retains his existing compensation through the transition period, and a separate consulting agreement with additional compensation is under negotiation.